Edison Expands its European Pharmaceutical Coverage by Initiating on MagForce

Nov 27, 2013, 09:19 ET from Edison Investment Research

LONDON, November 27, 2013 /PRNewswire/ --

Edison Investment Research, a leading international investment research firm, announces the initiation of coverage of MagForce (MF6), a German firm with a European approved nanotechnology-based therapy to treat brain tumours.

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

Edison's report, Coming out in Force, examines MagForce's ability to execute on its strategy to increase uptake of its novel NanoTherm therapy, already approved in Europe for brain cancer. MagForce has worked closely with a number of key opinion leaders to design a new glioblastoma (GBM) study, starting imminently, to help increase physician acceptance and awareness of the therapy. It also intends to enter the US market and develop NanoTherm therapy for prostate cancer. Edison's risk-adjusted valuation is €197m or €8.2/share.

For the full report see: http://www.edisoninvestmentresearch.com/research/company/magforce

About Edison Investment Research

The launch of coverage on MagForce is part of a programme of research initiations on bio-pharmaceutical companies exposed to global market opportunities. Edison provides detailed research coverage on more than 150 pharmaceutical and healthcare companies in Europe, North America, Australia and New Zealand. Its team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. It provides services to more than 400 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. All reports Edison publishes are available to download free of charge from its website http://www.edisongroup.com.

Edison is authorised and regulated by the Financial Services Authority (http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

About Magforce

MagForce is a German firm with a European approved nanotechnology-based therapy to treat brain tumours. NanoTherm therapy consists of nanoparticle injection into the tumour, activated by an external magnetic field, producing heat and thermally destroying or sensitising the tumour.

For more information please contact:

Dr Philippa Gardner, Edison Investment Research, +44(0)20-3681-2521

SOURCE Edison Investment Research